Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of Digoxin Combined With Fruquintinib and Tislelizumab in Patients With Advanced Primary Colorectal Cancer Who Failed Standard Therapy

NCT07025850 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07025850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07025850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of Digoxin Combined With Fruquintinib and Tislelizumab in Patients With Advanced Primary Colorectal Cancer Who Failed Standard Therapy
Lead sponsor
Fudan University
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
August 1, 2025
Completion date
May 1, 2027
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma